---
title: "Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282581233.md"
description: "Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?"
datetime: "2026-04-13T19:03:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282581233.md)
  - [en](https://longbridge.com/en/news/282581233.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282581233.md)
generator: "portal-rs"
---

# Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?


### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.](https://longbridge.com/en/news/297423774.md)
- [Revolution Medicines Got Its Breakthrough—What Moves It Next?](https://longbridge.com/en/news/298062833.md)
- [Revolution Medicines director Lorence H. Kim disposes of common shares worth $11.21 million](https://longbridge.com/en/news/297827433.md)
- [BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era](https://longbridge.com/en/news/297178071.md)
- [Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/297408646.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**